Context

Our client is a global biopharmaceutical leader known for pioneering biosimilars and investing heavily in novel drug development. They are now expanding their pipeline through external innovation and strategic partnerships.  

Our client is scouting for modalities like Drug Delivery Systems, Peptides, Nucleic Acid Therapies (NATs), and Antibodies in the therapeutic areas of Immunology, Oncology, and Metabolic Diseases.

VentureBlick is involved in scouting for relevant technologies to provide the client with companies suitable for

• Joint Research Agreements (with possible equity investment)

• Platform Technology Licensing

• Product In-Licensing

• Distribution Rights Acquisition

The client has a good history of successful commercial partnerships. A recent example of partnership is their deal in 2023 with a biotech company developing next-generation ADCs, to co-develop and commercialize their lead asset. The deal was valued at up to 1 billion USD.

Experts Needed

Global industry experts with deep expertise in the research and development of biotherapeutic products and the commercial adoption of novel technologies in the above modalities.

Advisors with a scientific or PhD background and/or experience with R&D in pharmaceutical applications are preferred.

Expert Involvement

Experts will be required to review the longlist of tech provider companies for a suitable match based on defined criteria and a scoring system. Company profiles shall be provided for detailed review of technology offerings.

Shortlisted advisors shall be provided with all materials to follow this process over email.

Note

If your expertise aligns with this project, we encourage you to apply for consideration. Only shortlisted advisors will be contacted for follow-ups.

For specific questions regarding eligibility or other inquiries, please reach out via the contact details below.